Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $7.6667.

A number of equities analysts have commented on the stock. William Blair raised shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Guggenheim reissued a “buy” rating and issued a $14.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, March 31st. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, March 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Tuesday, April 21st.

Neumora Therapeutics Stock Performance

Shares of NASDAQ NMRA opened at $1.60 on Thursday. The firm has a fifty day moving average price of $1.98 and a 200-day moving average price of $2.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 5.09 and a quick ratio of 5.09. The stock has a market cap of $296.45 million, a PE ratio of -1.20 and a beta of 2.73. Neumora Therapeutics has a 1 year low of $0.72 and a 1 year high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. Equities analysts anticipate that Neumora Therapeutics will post -0.95 earnings per share for the current fiscal year.

Institutional Trading of Neumora Therapeutics

Several large investors have recently made changes to their positions in the business. Hsbc Holdings PLC purchased a new stake in Neumora Therapeutics during the fourth quarter worth $27,000. Virtu Financial LLC purchased a new position in Neumora Therapeutics during the third quarter valued at $31,000. Legacy Private Trust Co. lifted its holdings in Neumora Therapeutics by 35.7% during the fourth quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock valued at $34,000 after purchasing an additional 5,000 shares in the last quarter. Fred Alger Management LLC purchased a new position in Neumora Therapeutics during the fourth quarter valued at $40,000. Finally, Canada Pension Plan Investment Board purchased a new position in Neumora Therapeutics during the second quarter valued at $41,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.